Cardiac morbidity and mortality related to orthotopic liver transplantation

Liver Transplantation

Volumn 10, Issue 12, 2004, Pages 1441-1453

  Therapondos, George ^a   Flapan, Andrew D ^b   Plevris, John N ^b   Hayes, Peter C ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMMUNE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ALCOHOLIC CARDIOMYOPATHY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; GRAFT REJECTION; HEART DISEASE; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART PRELOAD; HEMOCHROMATOSIS; HEPATOPULMONARY SYNDROME; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; LUNG EDEMA; MEDICAL ASSESSMENT; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; THROMBOEMBOLISM;

HEART DISEASES; HUMANS; IMMUNOSUPPRESSION; INTRAOPERATIVE COMPLICATIONS; LIVER DISEASES; LIVER TRANSPLANTATION; RISK FACTORS; TIME FACTORS;

EID: 11144313630     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20298     Document Type: Review

References (137)

1. Zetterman RK, Belle SH, Hoofnagle JH, Lawlor S, Wei Y, Everhart J, et al. Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation 1998;66:500-506.
2. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;6(Suppl 1):S44-S52.
3. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-1033.
4. Abelmann WH, Kowalski HJ, McNeely WF. The hemodynamic response to exercise in patients with Laennec's cirrhosis. J Clin Invest 1955;34:690-695.
5. Ahmed SS, Howard M, ten Hove W, Leevy CM, Regan TJ. Cardiac function in alcoholics with cirrhosis: absence of overt cardiomyopathy - myth or fact? J Am Coll Cardiol 1984;3:696-702.
6. Rector WG, Jr., Adair O, Hossack KF, Rainguet S. Atrial volume in cirrhosis: relationship to blood volume and plasma concentration of atrial natriuretic factor. Gastroenterology 1990;99:766-770.
7. Moller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
8. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46-51.
9. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996;2:426-430.
10. Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995;59:859-864.
11. Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992;15:858-862.
12. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996;61:1180-1188.
13. Stahl RL, Duncan A, Hooks MA, Henderson JM, Millikan WJ, Warren WD. A hypercoagulable state follows orthotopic liver transplantation. Hepatology 1990;12(Pt 1):553-558.
14. Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989;320:409-415.
15. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10:174-182.
16. Castro M, Krowka MJ. Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Clin Chest Med 1996;17:35-48.
17. Carey EJ, Douglas DD, Balan V, Vargas HE, Byrne TJ, Moss AA, et al. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: a single-center experience. Liver Transpl 2004;10:529-533.
18. Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003;125:1042-1052.
19. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993;104:515-521.
20. Taille C, Cadranel J, Bellocq A, Thabut G, Soubrane O, Durand F, et al. Liver transplantation for hepatopulmonary syndrome: a ten-year experience in Paris, France. Transplantation 2003;75:1482-1489.
21. Egawa H, Kasahara M, Inomata Y, Uemoto S, Asonuma K, Fujita S, et al. Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications. Transplantation 1999;67:712-717.
22. Krowka MJ, Porayko MK, Plevak DJ, Pappas SC, Steers JL, Krom RA, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997;72:44-53.
23. Cremona G, Higenbottam TW, Mayoral V, Alexander G, Demoncheaux E, Borland C, et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 1995;8:1883-1885.
24. Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113:606-614.
25. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome. N Engl J Med 1994;331:1098.
26. Schenk P, Madl C, Rezaie-Majd S, Lehr S, Muller C. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000;133:701-706.
27. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
28. Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002;8:382-388.
29. Schott R, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement of pulmonary hypertension after liver transplantation. Chest 1999;115:1748-1749.
30. Tarquino M, Geggel RL, Strauss RS, Rhodes J, Wunderlich B, Rohrer RJ. Treatment of pulmonary hypertension with inhaled nitric oxide during hepatic transplantation in an adolescent: reversibility of pulmonary hypertension after transplantation. Clin Pediatr (Phila) 1998;37:505-509.
31. Levy MT, Torzillo P, Bookallil M, Sheil AG, McCaughan GW. Case report: delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol 1996;11:734-737.
32. Mandell MS, Groves BM, Duke J. Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation 1995;59:1488-1490.
33. Koneru B, Ahmed S, Weisse AB, Grant GP, McKim KA. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994;58:1133-1135.
34. Scott V, De Wolf A, Kang Y, Martin M, Selby R, Fung J, et al. Reversibility of pulmonary hypertension after liver transplantation: a case report. Transplant Proc 1993;25:1789-1790.
35. Rassiat E, Barriere E, Durand F, Bernuau J, Belghiti J, Valla D, et al. Pulmonary hemodynamics and gas exchange after liver transplantation in patients with cirrhosis. Dig Dis Sci 2002;47:746-749.
36. Rafanan AL, Maurer J, Mehta AC, Schilz R. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest 2000;118:1497-1500.
37. Prager MC, Cauldwell CA, Ascher NL, Roberts JP, Wolfe CL. Pulmonary hypertension associated with liver disease is not reversible after liver transplantation. Anesthesiology 1992;77:375-378.
38. Kett DH, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001;7:645-648.
39. Ho MC, Hu RH, Ni YH, Lai HS, Ko WJ, Chang MH, et al. Liver transplantation in a patient with pulmonary hypertension. Transplant Proc 2000;32:2179-2181.
40. Levine JM, Kindscher JD. Cardiac failure after orthotopic liver transplantation. Anesth Analg 1994;78:179-180.
41. Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, et al. Long-term follow-up after liver transplantation in patients with hepatic iron overload. Liver Transpl Surg 1999;5:369-374.
42. Farrell FJ, Nguyen M, Woodley S, Imperial JC, Garcia-Kennedy R, Man K, et al. Outcome of liver transplantation in patients with hemochromatosis. Hepatology 1994;20:404-410.
43. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 1998;129:946-953.
44. Hetet G, Elbaz A, Gariepy J, Nicaud V, Arveiler D, Morrison C, et al. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest 2001;31:382-388.
45. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001;154:739-746.
46. Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 1994;272:231-233.
47. Niederau C. Iron overload and atherosclerosis. Hepatology 2000;32:672-674.
48. Harley ID, Jones EF, Liu G, McCall PR, McNicol PL. Orthotopic liver transplantation in two patients with hypertrophic obstructive cardiomyopathy. Br J Anaesth 1996;77:675-677.
49. Plevak DJ. Stress echocardiography identifies coronary artery disease in liver transplant candidates. Liver Transpl Surg 1998;4:337-339.
50. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999;67:1087-1093.
51. De Wolf A. Transesophageal echocardiography and orthotopic liver transplantation: general concepts. Liver Transpl Surg 1999;5:339-340.
52. Marquez J, Martin D, Virji MA, Kang YG, Warty VS, Shaw B, Jr., et al. Cardiovascular depression secondary to ionic hypocalcemia during hepatic transplantation in humans. Anesthesiology 1986;65:457-461.
53. Scott VL, De Wolf AM, Kang Y, Altura BT, Virji MA, Cook DR, et al. Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation: a complication of citrate intoxication. Liver Transpl Surg 1996;2:343-347.
54. Ranasinghe DN, Mallett SV. Hypomagnesaemia, cardiac arrhythmias and orthotopic liver transplantation. Anaesthesia 1994;49:403-405.
55. Pomposelli JJ, Pomfret EA, Burns DL, Lally A, Sorcini A, Gordon FD, et al. Life-threatening hypophosphatemia after right hepatic lobectomy for live donor adult liver transplantation. Liver Transpl 2001;7:637-642.
56. George R, Shiu MH. Hypophosphatemia after major hepatic resection. Surgery 1992;111:281-286.
57. Pinson CW, Daya MR, Benner KG, Norton RL, Deveney KE, Ascher NL, et al. Liver transplantation for severe Amanita phalloides mushroom poisoning. Am J Surg 1990;159:493-499.
58. Yu GC, Lee DB. Clinical disorders of phosphorus metabolism. West J Med 1987;147:569-576.
59. De Wolf A. Monitoring and handling of reperfusion. Liver Transpl Surg 1997;3:459-461.
60. Merritt WT. Complications of liver transplantation: a perioperative perspective. Liver Transpl Surg 1999;5:342-344.
61. Aggarwal S, Kang Y, Freeman JA, Fortunato FL, Jr., Pinsky MR. Postreperfusion syndrome: hypotension after reperfusion of the transplanted liver. J Crit Care 1993;8:154-160.
62. Pretto EA. Cardiac function after hepatic ischemia-anoxia and reperfusion injury: a new experimental model. Crit Care Med 1991;19:1188-1194.
63. De La Morena G, Acosta F, Villegas M, Bento M, Sansano T, Bueno FS, et al. Ventricular function during liver reperfusion in hepatic transplantation. A transesophageal echocardiographic study. Transplantation 1994;58:306-310.
64. Ellis JE, Lichtor JL, Feinstein SB, Chung MR, Polk SL, Broelsch C, et al. Right heart dysfunction, pulmonary embolism, and paradoxical embolization during liver transplantation. A transesophageal two-dimensional echocardiographic study. Anesth Analg 1989;68:777-782.
65. De Wolf AM, Begliomini B, Gasior TA, Kang Y, Pinsky MR. Right ventricular function during orthotopic liver transplantation. Anesth Analg 1993;76:562-568.
66. Prager MC, Gregory GA, Ascher NL, Roberts JP. Massive venous air embolism during orthotopic liver transplantation. Anesthesiology 1990;72:198-200.
67. Gologorsky E, De Wolf AM, Scott V, Aggarwal S, Dishart M, Kang Y. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 2001;7:783-789.
68. Steltzer H, Blazek G, Gabriel A, Leitner K, Mayer N, Muller C, et al. Two-dimensional transesophageal echocardiography in early diagnosis and treatment of hemodynamic disturbances during liver transplantation. Transplant Proc 1991;23:1957-1958.
69. Prah GN, Lisman SR, Maslow AD, Freeman RB, Rohrer RJ. Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during orthotopic liver transplantation - two case reports. Transplantation 1995;59:921-925.
70. Plotkin JS, Johnson LB, Kuo PC. Intracardiac thrombus formation during orthotopic liver transplantation: a new entity or an old enemy? Transplantation 1996;61:1131.
71. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant 1995;9:463-471.
72. Soresi M, Bascone F, Magliarisi C, Campagna P, Di Giovanni G, Riili A, et al. Hemodynamic changes in splanchnic circulation after orthotopic liver transplantation in patients with liver cirrhosis. Abdom Imaging 2002;27:541-545.
73. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999;30:58-64.
74. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC, Jr., et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993;55:1332-1339.
75. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906.
76. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl 2002;8:690-700.
77. Glanemann M, Kaisers U, Langrehr JM, Schenk R, Stange BJ, Muller AR, et al. Incidence and indications for reintubation during postoperative care following orthotopic liver transplantation. J Clin Anesth 2001;13:377-382.
78. Snowden CP, Hughes T, Rose J, Roberts DR. Pulmonary edema in patients after liver transplantation. Liver Transpl 2000;6:466-470.
79. Plevak DJ, Southorn PA, Narr BJ, Peters SG. Intensive-care unit experience in the Mayo liver transplantation program: the first 100 cases. Mayo Clin Proc 1989;64(4):433-445.
80. Garcia S, Ruza F, Gonzalez M, Roque J, Frias M, Calvo C et al. Evolution and complications in the immediate postoperative period after pediatric liver transplantation: our experience with 176 transplantations. Transplant Proc 1999;31:1691-1695.
81. Sampathkumar P, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, et al. Post-liver transplantation myocardial dysfunction. Liver Transpl Surg 1998;4:399-403.
82. Sankey EA, Crow J, Mallett SV, Alcock RJ, More L, Burroughs AK, et al. Pulmonary platelet aggregates: possible cause of sudden perioperative death in adults undergoing liver transplantation. J Clin Pathol 1993;46:222-227.
83. Rubin DA, Schulman DS, Edwards TD, Starzl TE, Curtiss EI. Myocardial ischemia after orthotopic liver transplantation. Am J Cardiol 1994;74:53-56.
84. Hadengue A, Lebrec D, Moreau R, Sogni P, Durand F, Gaudin C, et al. Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. Hepatology 1993;17:175-178.
85. Henderson JM, Mackay GJ, Hooks M, Chezmar JL, Galloway JR, Dodson TF, et al. High cardiac output of advanced liver disease persists after orthotopic liver transplantation. Hepatology 1992;15:258-262.
86. Odocha O, Jackson B, Zaheer R, Curry C. Liver transplantation in African-Americans with chronic alcoholic liver disease: focus on the elevated cardiac index pretransplantation. Transplant Proc 1997;29:3660-3661.
87. Gadano A, Hadengue A, Widmann JJ, Vachiery F, Moreau R, Yang S, et al. Hemodynamics after orthotopic liver transplantation: study of associated factors and long-term effects. Hepatology 1995;22:458-465.
88. Park SC, Beerman LB, Gartner JC, Zitelli BJ, Malatack JJ, Fricker FJ, et al. Echocardiographic findings before and after liver transplantation. Am J Cardiol 1985;55:1373-1378.
89. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 1999;30:58-64.
90. Lerman A, Click RL, Narr BJ, Wiesner RH, Krom RA, Textor SC, et al. Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. Transplantation 1991;51:646-650.
91. McNicol PL, Liu G, Shulkes A, Hardy KJ, Jones RM. Vasoactive intestinal peptide and calcitonin gene-related peptide levels and hemodynamics during human liver transplantation. Transplant Proc 1993;25:1830-1831.
92. Yokoyama I, Todo S, Miyata T, Selby R, Tzakis AG, Starzl TE. Endotoxemia and human liver transplantation. Transplant Proc 1989;21:3833-3841.
93. Acosta F, De La Morena G, Villegas M, Sansano T, Reche M, Beltran R, et al. Evaluation of cardiac function before and after liver transplantation. Transplant Proc 1999;31:2369-2370.
94. Garcia GM, Hernandez-Madrid A, Lopez-Sanroman A, Candela A, Nuno J, Barcena R. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. Transplant Proc 1999;31:2366-2367.
95. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, et al. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation. Evidence for early postoperative myocardial depression. Chest 1995;107:218-224.
96. Shoemaker WC, Appel PL, Kram HB. Hemodynamic and oxygen transport responses in survivors and nonsurvivors of high-risk surgery. Crit Care Med 1993;21:977-990.
97. Peng T, Lu X, Lei M, Moe GW, Feng Q. Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res 2003;59:893-900.
98. Grandel U, Fink L, Blum A, Heep M, Buerke M, Kraemer HJ, et al. Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Circulation 2000;102:2758-2764.
99. Meng X, Ao L, Meldrum DR, Cain BS, Shames BD, Selzman CH, et al. TNF-alpha and myocardial depression in endotoxemic rats: temporal discordance of an obligatory relationship. Am J Physiol 1998;275(Pt 2):R502-R508.
100. Bozkurt B, Kribbs SB, Clubb FJ, Jr., Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-1391.
101. Oral H, Dorn GW, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 1997;272:4836-4842.
102. Fernandez-Miranda C, Sanz M, dela Calle A, Loinaz C, Gomez R, Jimenez C, et al. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int 2002;15:556-562.
103. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000;69:781-789.
104. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906.
105. Clavien PA, Camargo CA, Jr., Croxford R, Langer B, Levy GA, Greig PD. Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg 1994;220:109-120.
106. Asfar S, Metrakos P, Fryer J, Verran D, Ghent C, Grant D, et al. An analysis of late deaths after liver transplantation. Transplantation 1996;61:1377-1381.
107. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, et al. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 1997;64:1801-1807.
108. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001;7:811-815.
109. Neuberger J. Liver transplantation. J Hepatol 2000;32(Suppl):198-207.
110. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg 2001;181:475-479.
111. Whitington PF, Alonso EM, Piper JB. Pediatric liver transplantation. Semin Liver Dis 1994;14:303-317.
112. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-896.
113. Scott JS, Boyle GJ, Daubeney PE, Miller SA, Law Y, Pigula F, et al. Tacrolimus: a cause of hypertrophic cardiomyopathy in pediatric heart transplant recipients? Transplant Proc 1999;31:82-83.
114. Baruch Y, Weitzman E, Markiewicz W, Eisenman A, Eid A, Enat R. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. Transplant Proc 1996;28:2250-2251.
115. Pappas PA, Weppler D, Pinna AD, Rusconi P, Thompson JF, Jaffe JS, et al. Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 2000;4:45-49.
116. Dollinger MM, Plevris JN, Chauhan A, MacGilchrist AJ, Finlayson ND, Hayes PC. Tacrolimus and cardiotoxicity in adult liver transplant recipients. Lancet 1995;346:507.
117. Cox TH, Baillie GM, Baliga P. Bradycardia associated with intravenous administration of tacrolimus in a liver transplant recipient. Pharmacotherapy 1997;17:1328-1330.
118. Nakata Y, Yoshibayashi M, Yonemura T, Uemoto S, Inomata Y, Tanaka K, et al. Tacrolimus and myocardial hypertrophy. Transplantation 2000;69:1960-1962.
119. Chang RK, McDiarmid SV, Alejos JC, Drant SE, Klitzner TS. Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation. Pediatr Transplant 2001;5:187-191.
120. Coley KC, Verrico MM, McNamara DM, Park SC, Cressman MD, Branch RA. Lack of tacrolimus-induced cardiomyopathy. Ann Pharmacother 2001;35:985-989.
121. Khanna A, Jain A, Ziady G, Demetris AJ, Fung JJ, Kramer D, et al. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. Transplant Proc 1997;29:532-533.
122. Roberts CA, Stern DL, Radio SJ. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. Transplantation 2002;74:817-821.
123. Mead J, Brady L, Cronin D, Loss G, Grewal H, Siegel C, et al. Neoral associated hypertrophic cardiomyopathy after pediatric liver transplantation. Pediatr Transplant 1998;2(Suppl 1):77.
124. Espino G, Denney J, Furlong T, Fitzsimmons W, Nash RA. Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. Bone Marrow Transplant 2001;28:1097-1103.
125. Brand PL, van Lingen RA, Brus F, Talsma MD, Elzenga NJ. Hypertrophic obstructive cardiomyopathy as a side effect of dexamethasone treatment for bronchopulmonary dysplasia. Acta Paediatr 1993;82:614-617.
126. Skelton R, Gill AB, Parsons JM. Cardiac effects of short course dexamethasone in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998;78:F133-F137.
127. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997;3:1-9.
128. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002;183:595-599.
129. Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004;18:463-472.
130. Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003;76:98-102.
131. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003;35(Suppl):209S-216S.
132. Kaplan MJ, Ellis CN, Bata-Csorgo Z, Kaplan RS, Endres JL, Fox DA. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch Dermatol 1999;135:553-557.
133. Stack WA, Mulcahy HE, Fenelon L, Hegarty JE. Cytomegalovirus myocarditis following liver transplantation. Postgrad Med J 1994;70:658-660.
134. Greenberg ML, Niebulski HI, Uretsky BF, Salerni R, Klein HA, Forstate WJ, et al. Occult purulent pericarditis detected by indium-111 leukocyte imaging. Chest 1984;85:701-703.
135. Hearn CJ, Smedira NG. Pulmonic valve endocarditis after orthotopic liver transplantation. Liver Transpl Surg 1999;5:456-457.
136. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003;9:451-462.
137. Chagas disease after organ transplantation - United States, 2001. MMWR Morb Mortal Wkly Rep 2002;51:210-212.